PACB - Pacific Biosciences of California, Inc.
MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.
PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.
SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers
Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
Autonomix Medical (NASDAQ: AMIX - Get Free Report) and Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation. Profitability This table compares Autonomix
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.71, marking a -1.16% move from the previous day.
PACB stock gains on Lucid Genomics deal, boosting HiFi data analysis and simplifying workflows to speed insights and expand adoption.
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem Expands access to streamlined genomic data analysis across the PacBio partner ecosystem
PACB stock rises after unveiling a new FFPE workflow with Covaris, boosting HiFi sequencing accuracy and unlocking insights from archived tumor samples.
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.6, marking a +1.91% move from the previous day.
New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.44, moving +1.41% from the previous trading session.